Trial reportEuropean journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology2026
Therapeutic efficacy of pharmacist-integrated clinic in evidence-based treatment for pediatric mycoplasma pneumoniae pneumonia.
Trial report in European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
This study aims to explore the therapeutic efficacy of evidence-based pharmaceutical interventions in pharmacist-integrated clinic for pediatric Mycoplasma pneumoniae pneumonia.A total of 200 children with suspected Mycoplasma pneumoniae pneumonia admitted to our hospital between July 2022 and June 2024 were enrolled and randomly assigned to either the intervention group or the control group using a random number method. The intervention group received standardized diagnostic and therapeutic procedures based on evidence-based medicine principles, while the control group received conventional treatment according to the doctor's standard practices. The two groups were compared regarding basic clinical parameters including time to defervescence, recovery duration, and medication use. Additionally, children treated with doxycycline underwent one-year dental follow-up.The intervention group demonstrated significantly better outcomes compared to controls across all measured parameters: time to defervescence (3.37±1.24 vs 4.77±1.21 d), recovery duration (9.37±4.26 vs 12.51±5.12 d), total treatment costs (¥769±452 vs ¥2988±1899), and medication course length (10.68±3.02 vs 14.88±4.36 d). Additionally, the intervention group showed lower hospitalization cases (8 vs 65), intravenous infusion cases (8 vs 65), and adverse drug reactions (7 vs 18). Notably, no cases of tooth yellowing were observed during the 12-month follow-up period in children who received doxycycline treatment.The evidence-based intervention via a pharmacist-integrated clinic significantly improved diagnostic accuracy and therapeutic efficacy for pediatric Mycoplasma pneumoniae pneumonia, with concomitant treatment costs reduction. No cases of doxycycline-induced tooth discoloration were observed.
Indexed as
Identifiers
41231384What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.